feprazone

Feprazone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolone class, structurally related to phenylbutazone but with a prenyl group instead of an n-butyl group. It is primarily indicated for the relief of pain and inflammation associated with arthritis, gout, rheumatic fever, and other musculoskeletal disorders. Feprazone acts mainly by inhibiting cyclooxygenase (COX)-2 activity, thereby reducing prostaglandin synthesis involved in inflammation and pain signaling. Additional mechanisms include inhibition of matrix metalloproteinases (MMP-2 and MMP-9), reduction in cell adhesion molecules such as VCAM-1 and ICAM-1, and suppression of the TLR4/MyD88/NF-kB signaling pathway implicated in inflammatory responses[1][4][5][6]. The drug has been tested in phase III clinical trials for conditions like osteoarthritis and rheumatoid arthritis; however, its current approval status is unclear[5].

Brand names

FeprazonePrenazone

Other names

prenazone